SCHEMBL16197340

SCHEMBL16197340

O=[N+]([O-])c1ccc(COC2CCCCO2)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HIF1A Q16665 1/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSP90AA1 P07900 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NPBWR1 P48145 1/20 0.35
MCHR1 Q99705 1/20 0.35
AR P10275 2/20 0.34
KDM4C Q9H3R0 1/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5078481 0.91 ALDH1A1 (0.40) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL5206947 0.80 IDO1 (0.46) ALDH1A1L3MBTL1SMN1; SMN2MAPTHTT
SCHEMBL30963217 0.79 EPHX2 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL31317363 0.79 ALDH1A1 (0.38) ALDH1A1L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL26668973 0.79 CXCR3 (0.41) L3MBTL1KMT2AMEN1KDM4C
SCHEMBL507078 0.79 NAAA (0.46) ALDH1A1L3MBTL1KMT2AMEN1KDM4C
SCHEMBL30029518 0.78 L3MBTL1 (0.41) ALDH1A1L3MBTL1HIF1AKMT2AMEN1
SCHEMBL16851818 0.78 L3MBTL1 (0.41) ALDH1A1L3MBTL1HIF1AKMT2AMEN1
SCHEMBL5083034 0.78 SMN1; SMN2 (0.42) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL8862264 0.77 CYP19A1 (0.41) CYP1A2CYP3A4CYP2C19ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340560-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEIGENE SWITZERLAND GMBH (CH) 2025-11-06 US disclosed
US-20240254128-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEIGENE SWITZERLAND GMBH (CH) 2024-08-01 US disclosed
US-20230013862-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEIGENE SWITZERLAND GMBH (CH) 2023-01-19 US disclosed
US-11142528-B2 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BEIGENE SWITZERLAND GMBH (CH) 2021-10-12 US disclosed
US-20200148690-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEONE MEDICINES I GMBH (CH) 2020-05-14 US disclosed
US-10570139-B2 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BEIGENE SWITZERLAND GMBH (CH) 2020-02-25 US disclosed
US-20180251466-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEIGENE, LTD. (KY) 2018-09-06 US disclosed
US-10005782-B2 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (KY) 2018-06-26 US disclosed
US-20170073349-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BEIGENE, LTD. (KY) 2017-03-16 US disclosed
US-20170073349-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BEIGENE, LTD. (KY) 2017-03-16 US disclosed
EP-2989106-B1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BEIGENE LTD (KY) 2016-12-14 EP disclosed
US-9447106-B2 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (KY) 2016-09-20 US disclosed
US-9447106-B2 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (KY) 2016-09-20 US disclosed
US-20160083392-A1 Fused heterocyclic compounds as protein kinase inhibitors BEIGENE, LTD. (KY) 2016-03-24 US disclosed
US-20160083392-A1 Fused heterocyclic compounds as protein kinase inhibitors BEIGENE, LTD. (KY) 2016-03-24 US disclosed
EP-2989106-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Beigene, Ltd. (KY) 2016-03-02 EP disclosed
US-20150259354-A1 Fused heterocyclic compounds as protein kinase inhibitors BEIGENE, LTD. (KY) 2015-09-17 US disclosed
US-20150259354-A1 Fused heterocyclic compounds as protein kinase inhibitors BEIGENE, LTD. (KY) 2015-09-17 US disclosed
WO-2014173289-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BEIGENE, LTD. (KY) 2014-10-30 WO disclosed
WO-2014173289-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BEIGENE, LTD. (KY) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254128-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-20180251466-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-10570139-B2 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-10005782-B2 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-20150259354-A1 Fused heterocyclic compounds as protein kinase inhibitors BTK, WEE1, LYN CYP1A2 3521/4885CYP3A4 2587/4885CYP2C9 2155/4885
US-20200148690-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-20170073349-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS BTK, WEE1, LYN CYP1A2 3521/4885CYP3A4 2587/4885CYP2C9 2155/4885
US-11142528-B2 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-20160083392-A1 Fused heterocyclic compounds as protein kinase inhibitors BTK, WEE1, LYN CYP1A2 3521/4885CYP3A4 2587/4885CYP2C9 2155/4885
US-20230013862-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885
US-20250340560-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK CYP1A2 3186/4885CYP3A4 2500/4885CYP2C9 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.